An international clinical trial led by the University of British Columbia reported results in advanced atrial fibrillation that challenge the default approach of beginning with medication. Published in the New England Journal of Medicine, the study found that starting with a minimally invasive strategy improved outcomes compared with an initial medication-first pathway. The trial’s design and endpoints will likely shape how electrophysiology and cardiology teams think about sequencing treatment, particularly for patients who have progressed beyond early-stage AF management. With device and drug manufacturers competing for earlier intervention windows, evidence that supports procedural-first approaches may accelerate guideline discussions and payer scrutiny.